The anti-diabetic medication like pioglitazone (18, 19), and Glucagon-like peptide-1 (GLP-1) receptor agonists (20, 21) have hinted promising results in patients with MASLD. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.